Paulo Ricardo Santos Nunes Filho
Paulo Ricardo Santos Nunes Filho has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Kamal S. Saini
Fortrea Inc., Durham, USA
3 shared publications - Ademar Dantas da Cunha Junior
Drug Development Division, Fortrea Inc., Durham, NC 27709, USA
2 shared publications - Cíntia Junges
Universidade Federal do Rio Grande do Sul (UFRGS), Programa de Pós Graduação em Saúde da Criança e do Adolescente, Porto Alegre, RS, Brazil
2 shared publications - Elza Daniel de Mello
Postgraduate Program in Child and Adolescent Health Universidade Federal Do Rio Grande Do Sul Porto Alegre Rio Grande do Sul Brazil
2 shared publications - José Barreto Campello Carvalheira
Department of Radiology and Oncology, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
2 shared publications - Laura Vidal
Fortrea Inc., Durham, USA
2 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70620
Human Absorption, Metabolism, and Excretion ( hAME ) Mass Balance Studies in Patients With Cancer
Radiolabeled mass balance human studies are a critical component of clinical pharmacology programs supporting the development of new investigational drugs. These studies provide information about absorption, metabolism, and excretion (AME) of the parent drug and metabolite(s) in the human body and are normally conducted in healthy volunteers (HVs). However, in some instances, based on the characteristics and toxicity of the molecule, conducting the study in HVs may not be a viable option and therefore cancer patients (CPs) need to be enrolled. Successful navigation of aspects such as pharmacologic characteristics, dose administration, patient clinical status and comorbidities, confinement period, study extension, team training, and requirements of the hospitals/units are essential to successfully deliver radiolabeled mass balance studies in CPs. This article provides an overview of the main aspects that must be taken into consideration to conduct AME studies in CPs.
- 29 May 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70620
Open AccessHuman Absorption, Metabolism, and Excretion ( hAME ) Mass Balance Studies in Patients With Cancer
Radiolabeled mass balance human studies are a critical component of clinical pharmacology programs supporting the development of new investigational drugs. These studies provide information about absorption, metabolism, and excretion (AME) of the parent drug and metabolite(s) in the human body and are normally conducted in healthy volunteers (HVs). However, in some instances, based on the characteristics and toxicity of the molecule, conducting the study in HVs may not be a viable option and therefore cancer patients (CPs) need to be enrolled. Successful navigation of aspects such as pharmacologic characteristics, dose administration, patient clinical status and comorbidities, confinement period, study extension, team training, and requirements of the hospitals/units are essential to successfully deliver radiolabeled mass balance studies in CPs. This article provides an overview of the main aspects that must be taken into consideration to conduct AME studies in CPs.
- Open Access
The Role of Metabolic Inflammation and Insulin Resistance in Obesity-Associated Carcinogenesis–A Narrative Review
The inflammatory milieu surrounding tumors plays a pivotal yet paradoxical role in promoting carcinogenesis. Rather than simply acting as a host defense mechanism, chronic low-grade inflammation actively nurtures tumor development and supports hallmarks such as sustained proliferative signaling, apoptosis resistance, angiogenesis, and metastasis. Obesity, characterized by a chronic inflammatory state, exacerbates this tumor-promoting environment through metabolic imbalances like insulin resistance, hyperglycemia, and dyslipidemia. These conditions stimulate oncogenic signaling pathways and reshape the tumor microenvironment. Obesity-associated cytokines, altered adipokines, and insulin-related growth signals synergistically enhance processes such as epithelial-to-mesenchymal transition (EMT) and matrix remodeling. This review explores the mechanistic interplay between obesity-induced inflammation and insulin resistance in cancer progression, discusses the molecular pathways involved, and highlights emerging therapeutic approaches targeting these intersecting tumor promotion axes.
Open AccessThe Role of Metabolic Inflammation and Insulin Resistance in Obesity-Associated Carcinogenesis–A Narrative Review
The inflammatory milieu surrounding tumors plays a pivotal yet paradoxical role in promoting carcinogenesis. Rather than simply acting as a host defense mechanism, chronic low-grade inflammation actively nurtures tumor development and supports hallmarks such as sustained proliferative signaling, apoptosis resistance, angiogenesis, and metastasis. Obesity, characterized by a chronic inflammatory state, exacerbates this tumor-promoting environment through metabolic imbalances like insulin resistance, hyperglycemia, and dyslipidemia. These conditions stimulate oncogenic signaling pathways and reshape the tumor microenvironment. Obesity-associated cytokines, altered adipokines, and insulin-related growth signals synergistically enhance processes such as epithelial-to-mesenchymal transition (EMT) and matrix remodeling. This review explores the mechanistic interplay between obesity-induced inflammation and insulin resistance in cancer progression, discusses the molecular pathways involved, and highlights emerging therapeutic approaches targeting these intersecting tumor promotion axes.
- Open Access
- 21 August 2025
- Published by MDPI AG in Preprints.org
The Role of Metabolic Inflammation and Insulin Resistance in Obesity-Associated Carcinogenesis
The inflammatory milieu surrounding tumors plays a pivotal yet paradoxical role in promoting carcinogenesis. Rather than simply acting as a host defense mechanism, chronic low-grade inflammation actively nurtures tumor development and supports hallmarks such as sustained proliferative signaling, apoptosis resistance, angiogenesis, and metastasis. Obesity, characterized by a chronic inflammatory state, exacerbates this tumor-promoting environment through metabolic imbalances like insulin resistance, hyperglycemia, and dyslipidemia. These conditions stimulate oncogenic signaling pathways and reshape the tumor microenvironment. Obesity-associated cytokines, altered adipokines, and insulin-related growth signals synergistically enhance processes such as epithelial-to-mesenchymal transition (EMT) and matrix remodeling. This review explores the mechanistic interplay between obesity-induced inflammation and insulin resistance in cancer progression, discusses the molecular pathways involved, and highlights emerging therapeutic approaches targeting these intersecting tumor promotion axes.
- 21 August 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Role of Metabolic Inflammation and Insulin Resistance in Obesity-Associated Carcinogenesis
The inflammatory milieu surrounding tumors plays a pivotal yet paradoxical role in promoting carcinogenesis. Rather than simply acting as a host defense mechanism, chronic low-grade inflammation actively nurtures tumor development and supports hallmarks such as sustained proliferative signaling, apoptosis resistance, angiogenesis, and metastasis. Obesity, characterized by a chronic inflammatory state, exacerbates this tumor-promoting environment through metabolic imbalances like insulin resistance, hyperglycemia, and dyslipidemia. These conditions stimulate oncogenic signaling pathways and reshape the tumor microenvironment. Obesity-associated cytokines, altered adipokines, and insulin-related growth signals synergistically enhance processes such as epithelial-to-mesenchymal transition (EMT) and matrix remodeling. This review explores the mechanistic interplay between obesity-induced inflammation and insulin resistance in cancer progression, discusses the molecular pathways involved, and highlights emerging therapeutic approaches targeting these intersecting tumor promotion axes.
- Open Access
- 14 March 2023
- Published by Springer Nature in Oncology and Therapy
- Vol. 11 (2) , 171-183
Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
Breast cancer is the most frequently diagnosed malignancy in patients worldwide and the main cause of cancer-related death. Though still incurable, metastatic breast cancer’s prognosis has been considerably improved in the past 10 years due to the introduction of new targeted agents, such as immune checkpoint inhibitors (ICI). However, these medications are associated with unique side effects known as immune-mediated adverse events (irAE). In this paper, we review the clinical evidence for the use of ICIs in breast cancer, in both the metastatic as well as neoadjuvant/adjuvant setting, followed by a review of irAE most commonly seen, and the medications used to treat them. Our opinion is that any cancer specialist treating patients with breast cancer should be aware of these side effects for early detection and management, and oncologists should be the leaders of the multidisciplinary team that will take care of them.
- 14 March 2023
- Published by Springer Nature in Oncology and Therapy
- Vol. 11 (2) , 171-183
Open AccessImmune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
Breast cancer is the most frequently diagnosed malignancy in patients worldwide and the main cause of cancer-related death. Though still incurable, metastatic breast cancer’s prognosis has been considerably improved in the past 10 years due to the introduction of new targeted agents, such as immune checkpoint inhibitors (ICI). However, these medications are associated with unique side effects known as immune-mediated adverse events (irAE). In this paper, we review the clinical evidence for the use of ICIs in breast cancer, in both the metastatic as well as neoadjuvant/adjuvant setting, followed by a review of irAE most commonly seen, and the medications used to treat them. Our opinion is that any cancer specialist treating patients with breast cancer should be aware of these side effects for early detection and management, and oncologists should be the leaders of the multidisciplinary team that will take care of them.
- Open Access
- 1 September 2020
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 96 (5) , 559-568
Vitamin D deficiency in pediatric patients using antiepileptic drugs: systematic review with meta‐analysis
- 1 September 2020
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 96 (5) , 559-568
Open AccessVitamin D deficiency in pediatric patients using antiepileptic drugs: systematic review with meta‐analysis
- Open Access
- 12 March 2020
- Published by Elsevier in Jornal de Pediatria
- Vol. 96 (5) , 559-568
Vitamin D deficiency in pediatric patients using antiepileptic drugs: systematic review with meta-analysis
- 12 March 2020
- Published by Elsevier in Jornal de Pediatria
- Vol. 96 (5) , 559-568
Open AccessVitamin D deficiency in pediatric patients using antiepileptic drugs: systematic review with meta-analysis